Core Viewpoint - Solo Brands, Inc. is appealing the NYSE Regulation's decision to delist its Class A common stock due to "abnormally low" price levels, with the aim of restoring compliance with NYSE listing standards [1][2][4]. Group 1: Company Actions and Status - The NYSE Regulation staff determined that Solo Brands' Class A common stock was unsuitable for listing, leading to a trading halt and current quotation on the OTC Pink Market under the symbol "DTCB" [2][3]. - The company plans to continue operating in compliance with SEC regulations and NYSE listing requirements during the appeal period [5]. - If the appeal is successful, trading of the Class A common stock may resume on the NYSE [3]. Group 2: Company Perspective - The interim President and CEO of Solo Brands stated that the current trading price and market capitalization do not reflect the company's value, prompting the appeal [4]. - The company is committed to executing action plans, including a reverse stock split, to restore compliance with NYSE standards [4]. Group 3: Company Overview - Solo Brands is headquartered in Grapevine, TX, and operates a portfolio of lifestyle brands, including Solo Stove, Chubbies, Isle, and Oru, focusing on innovative outdoor and apparel products [6].

Core Viewpoint - Jin Medical International Ltd. has received a deficiency letter from Nasdaq regarding non-compliance with the minimum bid price requirement for its ordinary shares, which must be at least $1.00 per share for continued listing on The Nasdaq Capital Market [1][2]. Compliance Status - The deficiency notice does not immediately affect the listing status of the ordinary shares, and the company has a compliance period of 180 calendar days, until October 29, 2025, to regain compliance [2][3]. - If the closing bid price reaches or exceeds $1.00 for a minimum of 10 consecutive business days before the deadline, the company will be notified of compliance [2]. Reverse Stock Split - The company may implement a reverse stock split to regain compliance, which must be completed no later than ten business days prior to October 29, 2025 [2][4]. - If the company fails to regain compliance within the initial 180-day period, it may be eligible for an additional compliance period, provided it meets other listing requirements [3][4]. Company Overview - Jin Medical International Ltd. was founded in 2006 and is headquartered in Changzhou, Jiangsu Province, China, focusing on designing, developing, manufacturing, and marketing wheelchairs and living aids for people with disabilities and the elderly [5]. - The company operates two manufacturing plants totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou, Anhui Province [5]. - Jin Medical has over 40 distributors in China and more than 20 international distributors, with a significant portion of its wheelchair products sold to Japan and China [5].

Core Points - TransCode Therapeutics has announced a 1-for-28 reverse stock split effective at 12:01 a.m. Eastern Standard Time on May 15, 2025, to increase the per share trading price and meet Nasdaq listing requirements [1][2] - The reverse stock split will reduce the number of outstanding shares from approximately 23,341,336 to about 833,620 shares, with no fractional shares issued [2] - The company's CUSIP number will change to 89357L 501 as of the effective time of the reverse stock split [4] Company Overview - TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics, utilizing its proprietary TTX nanoparticle platform [5] - The lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis [5] - The company is also developing a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for cancer treatment [5]

Core Viewpoint - Vaxart, Inc. is urging stockholders to vote in favor of a reverse stock split proposal to maintain its Nasdaq listing and support ongoing vaccine development efforts [1][9][11] Recent Developments - A government stop work order was lifted on April 24, 2025, allowing Vaxart to proceed with its COVID-19 vaccine clinical trial, which is expected to secure non-dilutive government funding [3] - The company has completed enrollment for its norovirus program, with topline data anticipated in mid-2025, which could attract strategic partnerships and additional funding [4] Strategic Measures - Vaxart is implementing cost control measures, including workforce reductions, to extend its cash runway into 2026 while balancing cost savings with R&D investments [5] - The company is actively seeking additional sources of non-dilutive funding to support its initiatives [5] Stockholder Communication - Vaxart acknowledges stockholder concerns regarding stock performance and emphasizes the importance of compliance with SEC regulations in its communications [6] - The company will host a Q1 2025 earnings call on May 13, 2025, to provide updates and address stockholder questions [7] - A webcast presentation at the Citizens Life Sciences Conference on May 7, 2025, will also be available for stockholders [8] Reverse Stock Split Proposal - The reverse stock split proposal is aimed at preventing delisting from Nasdaq due to a minimum bid price requirement of $1.00 per share, with recommendations from leading proxy advisors to vote "FOR" the proposal [9][10] - The board intends to implement a reverse stock split only if necessary to maintain Nasdaq compliance, preferring to achieve compliance through stock price appreciation [10][11] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines, including candidates for COVID-19, norovirus, and HPV, utilizing a proprietary delivery platform [13]

Core Insights - The marijuana sector continues to face significant challenges, leading to a lack of investor interest, particularly as cannabis remains illegal at the federal level in the U.S. [1] - Tilray Brands has experienced a substantial decline in its stock value, losing over 26% in April and trading under $1, indicating a prolonged downward trend [1][4] - The company reported a 1% year-over-year decline in net revenue for fiscal Q3 2025, totaling just under $186 million, and posted a non-GAAP loss of $2.9 million compared to a profit of $885,000 in the same period the previous year [2][4] Financial Performance - Tilray's management has reduced its revenue guidance for 2025, now expecting $850 million to $900 million, down from a previous estimate of $950 million to $1 billion [4] - The company is considering a reverse stock split with a proposed ratio of 1-to-10 to 1-to-20 to boost its stock price, which will be voted on in a special shareholders' meeting on June 10 [5] Diversification Efforts - In an attempt to diversify, Tilray has been acquiring craft breweries, as beer has broader market appeal and is not subject to the same regulatory challenges as cannabis [7] - However, the beer market has also faced challenges, with consumption hitting a four-decade low in 2024, raising doubts about whether this strategy will improve Tilray's fortunes [8] Market Outlook - There are currently no clear catalysts for Tilray's recovery, with the only potential being the decriminalization of cannabis in the U.S., which appears unlikely in the near term [9]

Core Viewpoint - TransCode Therapeutics has announced a 1-for-28 reverse stock split to comply with Nasdaq's minimum bid price requirements, aiming to increase the trading price of its common stock [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert twenty-eight current shares into one new share, reducing the total outstanding shares from approximately 23,341,336 to about 833,620 [2]. - No fractional shares will be issued; instead, stockholders will receive rounding up of fractional shares to the nearest whole number [2]. - Proportional adjustments will be made to the exercise prices of outstanding stock options and warrants, as well as to the shares issued under stock incentive plans [2]. Group 2: Implementation and Process - Vstock Transfer LLC will serve as the exchange agent for the reverse stock split, and stockholders of record will not need to take action to receive their post-split shares [3]. - Stockholders holding shares through banks or brokers will have their positions automatically adjusted, but they may need to check with their respective institutions for specific procedures [3]. - The effective date of the reverse stock split will be announced by the company at least two business days prior to implementation [4]. Group 3: Company Overview - TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics [5]. - The company's lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [5]. - TransCode is also developing a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for cancer treatment [5].

Core Viewpoint - Wheels Up Experience Inc. is focused on improving profitability and expanding margins through fleet modernization, partnerships, and premium customer solutions [1][2]. Financial Compliance - Wheels Up received a notice from the NYSE on April 22, 2025, indicating that its average closing stock price was below $1.00 for 30 consecutive trading days, which is necessary for continued listing [1][3]. - The company has six months to regain compliance with the NYSE's minimum share price requirement and plans to seek stockholder approval for a reverse stock split at its annual meeting on June 10, 2025 [3]. Business Strategy - The company is committed to long-term operational improvements and aims to build a resilient business model for sustainable profitability [2]. - Key initiatives include modernizing its fleet with Embraer Phenom 300 and Bombardier Challenger 300 jets, leveraging a partnership with Delta Air Lines, and delivering premium solutions for customers [2]. Financial Position - As of December 31, 2024, Wheels Up had approximately $316 million in liquidity, consisting of about $216 million in unrestricted cash and an undrawn $100 million commitment from Delta [2]. Company Overview - Wheels Up is a leading provider of on-demand private aviation in the U.S., offering a diverse fleet and a global network of safety-vetted charter operators [4]. - The company provides charter and membership programs, as well as freight, safety, security, and managed services to various clients, including individuals and government organizations [4].

Core Points - Atos SE has completed a reverse stock split as decided by its Board of Directors on March 6, 2025, following a delegation of powers by the shareholders' General Meeting on January 31, 2025 [1][2][3] Summary by Sections Reverse Stock Split Details - The reverse stock split is a technical exchange transaction that does not affect the total value of shares held by shareholders [2] - The exchange ratio is 10,000 old shares with a par value of €0.0001 for 1 new share with a par value of €1 [9] - The total number of old shares subject to the reverse stock split was 190,358,728,519, resulting in 19,035,872 new shares [9] Shareholder Actions - Shareholders holding multiples of 10,000 shares do not need to take any action as their shares were automatically consolidated [4] - Shareholders with fractional rights will be compensated by their financial intermediaries within 30 days of April 24, 2025 [5] Adjustments Related to Warrants - The exercise parity of the share subscription warrants issued on December 18, 2024, has been adjusted in accordance with the reverse stock split [6][7] - The new exercise parity corresponds to the product of the previous exercise parity and the ratio of new shares to old shares, resulting in a maximum of 1,107,589 new ordinary shares available upon exercise [7] Adjustments for Free Share Allocations - The rights of beneficiaries of free share allocations have been adjusted to reflect the reverse stock split, with the number of rights allocated being rounded down to the nearest whole number if necessary [10][11] Trading and Timetable - The new shares began trading on Euronext Paris on April 24, 2025, under ISIN code FR001400X2S4 [9][12] - The compensation period for shareholders with fractional rights runs from April 24 to May 25, 2025 [12] Company Overview - Atos is a global leader in digital transformation with approximately 74,000 employees and annual revenue of around €10 billion [13] - The company specializes in cybersecurity, cloud, and high-performance computing, providing tailored solutions across 68 countries [13]

Core Viewpoint - X4 Pharmaceuticals has announced a one-for-thirty reverse stock split to address compliance issues with Nasdaq's minimum bid price requirement and to potentially increase the market price of its Common Stock [1][11]. Summary by Sections Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on April 28, 2025, with trading on a split-adjusted basis commencing on the same day [2]. - The split will consolidate every thirty shares into one, reducing the number of outstanding shares from approximately 173.6 million to about 5.8 million [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Shareholder Impact - No fractional shares will be issued; instead, shareholders entitled to fractional shares will receive cash [5]. - Stockholders with shares held in book-entry form or through intermediaries will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Compliance with Nasdaq - The reverse stock split was approved within the range disclosed at the 2025 Special Meeting of Stockholders held on April 17, 2025 [7]. - X4 received a deficiency letter from Nasdaq due to its stock price falling below the required minimum of $1.00 per share for 30 consecutive business days [8]. - The company was granted an additional 180-day compliance period until August 11, 2025, to regain compliance with the Bid Price Rule [10]. Company Strategy - X4 believes that the reverse stock split will help increase the market price of its Common Stock and address the deficiency in the Bid Price Rule [11].

Core Viewpoint - Femto Technologies Inc. has implemented a 1-for-500 reverse stock split to comply with Nasdaq's minimum bid price requirement for continued listing [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split became effective on April 22, 2025, and was approved by the board on April 10, 2025 [1]. - Following the split, the number of issued and outstanding subordinate voting shares decreased from approximately 299,848,784 to about 599,697 [4]. - The trading of subordinate voting shares will continue under the symbol "FMTO" with a new CUSIP number 31447N303 [2]. Group 2: Impact on Shareholders - Every 500 subordinate voting shares will be combined into one, with fractional shares rounded down or up based on specific criteria [3]. - The reverse stock split will uniformly affect all shareholders without altering their relative interest in the company's equity, except for adjustments related to fractional shares [3]. Group 3: Company Overview - Femto Technologies Inc., formerly known as BYND Cannasoft Enterprises Inc., is a public company focused on female wellness and has developed the Sensera product [5]. - The company's Smart Release System (SRS technology) is recognized in the CES Innovation Awards® 2025 in the AI category [5]. - Current devices are in the early development stage and will require testing and regulatory approvals before market release [5].